Homepage Top Section2

MAb-AR20.5 is an IgG1k type murine monoclonal antibody that attaches specifically to the circulating and tumour-associated antigen (MUC1) expressed on pancreatic cancer cells. It is said to become

The regulator has provided the Prescription Drug User Fee Act (PDUFA) date of 20 December this year for the review. Currently approved under accelerated approval, TARPEYO is developed

The Series B round was co-led by Redmile Group and Bain Capital Life Sciences. It saw participation of new and existing investors including RA Capital Management, Samsara BioCapital,

As per the terms of the deal, Sprint will receive $3m as upfront payment. Day One will also reimburse Sprint for pre-clinical research and development expenses. Additionally, Sprint

The regulatory agency has granted priority review for this NDA with Prescription Drug User Fee Act (PDUFA) target action date of 22 February next year. It earlier granted

Lilly signed the definitive agreement to acquire Versanis Bio in July this year. At the time of the deal announcement, its terms specified that shareholders of Versanis were

Stockholders of Chinook will receive $40.00 in cash per share, a total of $3.2bn, from Novartis. Upon achieving certain regulatory milestones, they will further receive $4.00 in cash

In June this year, the therapy, in combination with Genentech’s Tecentriq received FDA fast track designation (FTD) for the treatment of extensive-stage small cell lung cancer (ES-SCLC) patients.

The expansion involved addition of one 50L, two 200L, and two 1,000L suspension single-use bioreactors. It also offers the flexibility to accommodate up to four iCellis500 adherent single-use